Stock comparison
Haemonetics
Sanofi
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
SNY
Sanofi
Market cap
$106.67B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SNY | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 61C | HAE |
| Benjamin Graham | 85A | 40D | HAE |
| Philip Fisher | 60C | 53C | HAE |
| Peter Lynch | 54C | 39D | HAE |
| Joel Greenblatt | 31F | 39D | SNY |
| Charlie Munger | 54D | 48D | HAE |
| Terry Smith | 55D | 49D | HAE |
Side-by-side metrics
| Metric | HAE | SNY |
|---|---|---|
| Market cap | $2.98B | $106.67B |
| P/E (TTM) | 24.8x | 8.6x |
| EV/EBIT | 14.1x | 10.8x |
| ROIC (TTM) | 8.37% | 11.66% |
| Gross margin | 55.74% | 71.62% |
| Net margin | 7.29% | 17.59% |
| Revenue CAGR 5y | 7.65% | 4.5% |
| EPS CAGR 5y | 24.62% | 6.47% |
| Debt / Equity | 1.5x | 0.3x |
| Dividend yield | 0.0% | 5.57% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 6.47%+74%
- Revenue CAGR 5y7.65%vs 4.5%+41%
SNY leads on
- Dividend yield5.57%vs 0.0%+100%
- Market cap$106.67Bvs $2.98B+97%
- Debt / Equity0.3xvs 1.5x+82%
- P/E (TTM)8.6xvs 24.8x+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.